Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 28;29(23):5650.
doi: 10.3390/molecules29235650.

Graphene Oxide Nanoparticles for Photothermal Treatment of Hepatocellular Carcinoma Using Low-Intensity Femtosecond Laser Irradiation

Affiliations

Graphene Oxide Nanoparticles for Photothermal Treatment of Hepatocellular Carcinoma Using Low-Intensity Femtosecond Laser Irradiation

Charilaos Xenodochidis et al. Molecules. .

Abstract

Graphene oxide-mediated photothermal therapy using femtosecond lasers has recently shown promise in treating hepatocellular carcinoma. However, significant work remains to optimize irradiation parameters for specific nanoparticle types and cancer cells to improve nanomaterial-mediated photothermal anticancer therapy. This study investigated the photothermal potential of nGO and nGO-PEG nanoparticles (NPs) combined with femtosecond laser irradiation at 515 nm and 1030 nm wavelengths, with varying power (0.1 and 0.2 W/cm2) and duration (5 and 10 min), to optimize photothermal therapy for hepatocellular carcinoma. Conversion efficiency of NPs, morphology and viability of HepG2 and normal MDCK cells after treatments were evaluated using an electronic thermometer, phase-contrast microscopy, and WST-1 assay. The results revealed that nGO-PEG NPs exhibited better photothermal efficiency than nGO, with 515 nm of irradiation inducing a temperature increase up to 19.1 °C compared to 4.7 °C with 1030 nm of light. Laser exposure to 515 nm significantly reduced HepG2 cell viability, with the most intense conditions (10 min at 0.2 W/cm2) causing a decrease of up to 58.2% with nGO and 43.51% with nGO-PEG. Normal MDCK cells showed minimal impact or a slight viability increase, especially with nGO-PEG. Combined treatment with laser irradiation and NPs induced significant morphological changes in HepG2 cells, including cell detachment and apoptotic-like characteristics, particularly with 1030 nm of irradiation. MDCK cells exhibited minimal morphological changes, with some recovery observed under lower energy conditions. These findings suggest that low-energy lasers and engineered nanomaterials could provide a minimally invasive approach to photothermal cancer therapy with reduced side effects.

Keywords: 1030 nm light; 515 nm light; HepG2 cells; MDCK cells; cell viability; pulse laser.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Physiochemical properties of nGO and nGO-PEG NPs: TEM analysis of nGO (left) and nGO-PEG after sonication (right); UV-Vis adsorbance spectra of nGO and nGO-PEG non-irradiated.
Figure 2
Figure 2
Cell viability of HepG2 cells treated with nGO (A) and nGO-PEG NPs (B) with a concentration of 100 μg/mL, irradiated with a laser beam at 515 nm for 5 and 10 min and with power densities of 0.1 and 0.2 W/cm2. The results’ statistical significance was denoted as * p < 0.05; *** p < 0.005.
Figure 3
Figure 3
Cell viability of HepG2 cells treated with nGO (A) and nGO-PEG NPs (B) with a concentration of 100 μg/mL, irradiated with a laser beam at 1030 nm for 5 and 10 min and with power densities of 0.1 and 0.2 W/cm2. The results’ statistical significance was denoted as * p < 0.05, ** p < 0.01, and *** p < 0.005.
Figure 4
Figure 4
Cell viability of MDCK cells treated with nGO (A) and nGO-PEG NPs (B) with a concentration of 100 μg/mL, irradiated with a laser beam at 515 nm for 5 and 10 min and with power densities of 0.1 and 0.2 W/cm2.
Figure 5
Figure 5
Cell viability of MDCK cells treated with nGO (A) and nGO-PEG NPs (B) with a concentration of 100 μg/mL, irradiated with a laser beam at 1030 nm for 5 and 10 min and with power densities of 0.1 and 0.2 W/cm2.
Figure 6
Figure 6
Morphological changes in the HepG2 cell line treated with nGO and nGO-PEG NPs with a concentration of 100 μg/mL a day after irradiation with a laser beam at 515 nm (A) and 1030 nm (B) for 5 and 10 min and with power densities of 0.1 and 0.2 W/cm2.
Figure 7
Figure 7
Morphological changes in the MDCK cell line treated with nGO and nGO-PEG NPs with a concentration of 100 μg/mL a day after irradiation with a laser beam at 515 nm (A) and 1030 nm (B) for 5 and 10 min and with power densities of 0.1 and 0.2 W/cm2.

References

    1. Rumgay H., Arnold M., Ferlay J., Lesi O., Cabasag C.J., Vignat J., Laversanne M., McGlynn K.A., Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 2022;77:1598–1606. doi: 10.1016/j.jhep.2022.08.021. - DOI - PMC - PubMed
    1. Asafo-Agyei K.O., Samant H. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Hepatocellular Carcinoma. - PubMed
    1. Bakrania A., Zheng G., Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics. 2021;14:41. doi: 10.3390/pharmaceutics14010041. - DOI - PMC - PubMed
    1. Sadagopan N., He A.R. Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma. Int. J. Mol. Sci. 2024;25:1259. doi: 10.3390/ijms25021259. - DOI - PMC - PubMed
    1. Raoul J.L., Kudo M., Finn R.S., Edeline J., Reig M., Galle P.R. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat. Rev. 2018;68:16–24. doi: 10.1016/j.ctrv.2018.05.006. - DOI - PubMed

LinkOut - more resources